ArticleNPJ Parkinson's disease2026
Testing an inverse link between limbic alpha-synucleinopathy and myelin markers in mice and humans.
Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
In Lewy body disease, alpha-synucleinopathic inclusions tend to develop in brain regions that extend long, thin, and unmyelinated projection fibers, but it is not known if this selective vulnerability is caused by poor myelination status. Our objective was to investigate this link in the limbic forebrain. First, we observed that levels of insoluble, hyperphosphorylated alpha-synuclein correlated inversely with the myelin marker proteolipid protein (20 kDa isoform) in the amygdala of men (but not women) with Lewy body disease. Second, select oligodendrocytic markers were mildly suppressed in the amygdala of men with Lewy body disease. Third, preformed fibrils (PFFs) of alpha-synuclein tended to induce greater pathology in gray matter, even when infused into murine brain regions penetrated by myelinated fiber bundles. Given these correlative patterns, we tested the hypothesis that myelin disruption with pharmacologic or genetic tools will exacerbate the development of limbic alpha-synucleinopathy in mice of both sexes, using a full-factorial experimental design. In nontransgenic mice with retrobulbar infusions of PFFs, dietary exposure to the established myelin disruptor cuprizone modestly increased the fraction of Triton-insoluble alpha-synuclein that was hyperphosphorylated at serine 129 (pSer129). Contrary to our hypothesis, however, cuprizone did not induce systematic, robust worsening of most pSer129+ object attributes, behavior deficits, cellular toxicity measures (NeuN+/Hoechst+ object attributes), or pan-alpha-synuclein insolubility. Similarly, PFF-induced effects on the insolubility and hyperphosphorylation of alpha-synuclein, behavior measures, and pSer129+, NeuN+, and Hoechst+ object attributes were not markedly amplified in mice heterozygous for the shiverer mutation in myelin basic protein (Mbp
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.